Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Director | May 14, 2026 | May 14, 2026 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date May 14, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-05-13 | Direct | 9,149 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 9,149 · Balance 9,149 F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).
TANDEM DIABETES CARE INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,434 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Exercise / conversion · Acquired 8,759 · Balance 24,434 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 10,220 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 10,220 · Balance 10,220 F3: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Exercise / conversion · Disposed 8,759 · Balance 0 F3: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F5: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,112 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,112 F1: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 7,568 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,568 F2: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over these securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002.
F2: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over these securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein.
F3: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F4: RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan.
F5: On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SENOMYX INC
Report date November 02, 2018 · Filed November 02, 2018
Section 16 reporting ended · disclosed 2018-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2028-05-23 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2020 Filed Aug 5, 2020 00:11 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,500 | $106.53 | $266,312.50 |
DisclosureSEC source: 0001438133-20-000123 · wf-form4_159658620814357.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,500 F4 · kind: The shares were given as a bona fide gift to the Chris and Rebecca Twomey Family Foundation at the San Diego Foundation. F5 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| July 31, 2020 Filed Aug 5, 2020 00:11 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 5,000 | $110.06 | $550,319.50 |
DisclosureSEC source: 0001438133-20-000123 · wf-form4_159658620814357.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 30,000 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2020. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $110.00 and $110.67. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 20:40 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 2,500 | $100.02 | $250,061.50 |
DisclosureSEC source: 0001438133-20-000106 · wf-form4_159415442630280.xml · nonDerivative · entry 4 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 20,000 F7 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $100.00 and $100.53. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F8 · ownership.nature: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 20:40 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,500 | $101.26 | $253,150.00 |
DisclosureSEC source: 0001438133-20-000106 · wf-form4_159415442630280.xml · nonDerivative · entry 3 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 35,000 F5 · kind: The shares were given as a bona fide gift to the Chris and Rebecca Twomey Family Foundation at the San Diego Foundation. F6 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 20:40 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 1,062 | $101.17 | $107,438.40 |
DisclosureSEC source: 0001438133-20-000106 · wf-form4_159415442630280.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 37,500 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2020. F4 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $101.01 and $101.22. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 20:40 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 3,938 | $100.20 | $394,573.82 |
DisclosureSEC source: 0001438133-20-000106 · wf-form4_159415442630280.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 38,562 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2020. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $100.00 and $100.95. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 00:35 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040765 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 18, 2022 23:30 UTC Amendment | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-042486 · doc4a.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| May 27, 2020 Filed May 30, 2020 00:50 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 1,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-20-000079 · wf-form4_159079983658765.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892 Underlying: Common Stock · 1,892 shares Expires not disclosed F1 · security: Awarded on May 27, 2020 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F3 · derivative.exercise_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. F3 · derivative.expiration_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 2,500 | $90.00 | $225,001.00 |
DisclosureSEC source: 0001438133-20-000044 · wf-form4_158896945165455.xml · nonDerivative · entry 3 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 22,500 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2020. F6 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $90.00 and $90.010. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F7 · ownership.nature: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GiftCommon Stock | 2,500 | $88.60 | $221,487.50 |
DisclosureSEC source: 0001438133-20-000044 · wf-form4_158896945165455.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 42,500 F4 · kind: The shares were given as a bona fide gift to the Chris and Rebecca Twomey Family Foundation at the San Diego Foundation. F5 · price: The price per share reflects the average of the high and low trading prices of the Company's stock on the transaction date. F3 · ownership.nature: The securities are held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 5,000 | $90.04 | $450,213.50 |
DisclosureSEC source: 0001438133-20-000044 · wf-form4_158896945165455.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,000 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2020. F2 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $90.00 and $90.145. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. F3 · ownership.nature: The securities are held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| April 30, 2020 Filed May 4, 2020 22:12 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 1,758 | $80.00 | $140,640.00 |
DisclosureSEC source: 0001438133-20-000041 · wf-form4_158863033632595.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 25,000 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2020. F2 · shares: The shares were originally purchased between 2008-2012 as Series B-Series D preferred stock. F4 · ownership.nature: The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| April 30, 2020 Filed May 4, 2020 22:12 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 2,550 | $80.00 | $204,000.00 |
DisclosureSEC source: 0001438133-20-000041 · wf-form4_158863033632595.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 50,000 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2020. F2 · shares: The shares were originally purchased between 2008-2012 as Series B-Series D preferred stock. F3 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 18:50 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock Warrants (right to buy) · Derivative | 45,000 | $0.01 Strike: $0.33 | $450.00 |
DisclosureSEC source: 0001209191-20-023733 · doc4.xml · derivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2025-04-06 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated April 1, 2020 with a closing date of April 6, 2020. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.33. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.32 and per common warrant is $0.01. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 18:50 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 45,000 | $0.32 | $14,400.00 |
DisclosureSEC source: 0001209191-20-023733 · doc4.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 64,500 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated April 1, 2020 with a closing date of April 6, 2020. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.33. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.32 and per common warrant is $0.01. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 19:15 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock Warrants (right to buy) · Derivative | 9,500 | $0.01 Strike: $0.86 | $95.00 |
DisclosureSEC source: 0001209191-19-054082 · doc4.xml · derivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2024-10-23 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated October 21, 2019 with a closing date of October 23, 2019. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.86. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.85 and per common warrant is $0.01. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 19:15 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 9,500 | $0.85 | $8,075.00 |
DisclosureSEC source: 0001209191-19-054082 · doc4.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · C J TWOMEY & R J TWOMEY TTEES, C J & R J TWOMEY FAMILY TRUST, UAD 9/20/2002 Disclosed balance after: 19,500 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated October 21, 2019 with a closing date of October 23, 2019. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. F2 · price: The total per share and accompanying common warrant price offered in the public offering is $0.86. Each share of common stock is being sold together with a common warrant to purchase one share of the Company's common stock. The public offering price, per share is $0.85 and per common warrant is $0.01. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 22:43 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 3,732 | $0.00 Strike: $64.66 | $0.00 |
DisclosureSEC source: 0001209191-19-038311 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,732 Underlying: Common Stock · 3,732 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:36 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035905 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 23:27 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $33.12 | $0.00 |
DisclosureSEC source: 0001209191-18-059311 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:01 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-056988 · doc4.xml · derivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2028-05-23 F1 · price: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:01 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001209191-18-056988 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-05-10 F1 · price: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F1 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). The option was cancelled in connection with the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:36 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 10,516 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053828 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516 Underlying: Common Stock · 10,516 shares Expires 2028-09-30 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 36 months beginning on the one-month anniversary of October 1, 2018 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the three year anniversary of the Vesting Commencement Date. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:47 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 10,000 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0001209191-18-048553 · doc4.xml · derivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-08-21 F1 · price: Units purchased in the Issuer's Initial Public Offering for $6.125 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. F2 · derivative.exercise_date: 9/21/18 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:47 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 10,000 | $6.13 | $61,250.00 |
DisclosureSEC source: 0001209191-18-048553 · doc4.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Units purchased in the Issuer's Initial Public Offering for $6.125 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. Read SEC document |
| May 24, 2018 Filed May 25, 2018 17:01 UTC | SENOMYX INC SNMX · Entity 162645 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001437749-18-010754 · rdgdoc.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments beginning one month following the Date of Grant (5/24/2018). F2 · balance_after: The Reporting Person also holds outstanding options to purchase 181,300 shares of Common Stock Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 21:54 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 25,000 | $2.00 | $50,000.00 |
DisclosureSEC source: 0001209191-18-009605 · doc4.xml · nonDerivative · entry 2 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 26,758 F1 · shares: The reporting person has committed to purchase shares in connection with the Company's underwritten registered public offering of common stock. F2 · balance_after: The amount of securities beneficially owned following the reported transactions reflects the 10 for 1 reverse stock split of the Issuer's issued and outstanding common stock which was effective on October 9, 2017. F4 · ownership.nature: The securities are directly owed by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over the securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 21:54 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 50,000 | $2.00 | $100,000.00 |
DisclosureSEC source: 0001209191-18-009605 · doc4.xml · nonDerivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 52,550 F1 · shares: The reporting person has committed to purchase shares in connection with the Company's underwritten registered public offering of common stock. F2 · balance_after: The amount of securities beneficially owned following the reported transactions reflects the 10 for 1 reverse stock split of the Issuer's issued and outstanding common stock which was effective on October 9, 2017. F3 · ownership.nature: The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:03 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 5,300 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-17-064036 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over twelve (12) months. F3 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant. Read SEC document |
| November 15, 2017 Filed Nov 18, 2017 00:02 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Options · Derivative | 1,700 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-17-061635 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| May 11, 2017 Filed May 22, 2017 18:21 UTC | SENOMYX INC SNMX · Entity 162645 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001437749-17-009843 · rdgdoc.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-10 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments beginning one month following the Date of Grant (5/11/2017). Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 01:05 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Options · Derivative | 17,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-16-150725 · doc4.xml · derivative · entry 1 TWOMEY CHRISTOPHER J · CIK 0001238935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.